{"transactions":[{"id":810450,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2026-04-10T20:00:06.000Z","date":"2026-04-09","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable over four years, with 25% vesting on the one year anniversary of the grant date and the remainder vesting in equal, semi-annual installments thereafter."}],"balance_after":200000,"derivative":{"exercise_price":0.29,"expiration_date":"2036-04-08","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0001193125-26-151202","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000119312526151202/ownership.xml","form_type":"4"}},{"id":979099,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T23:54:26.000Z","date":"2025-12-03","kind":"grant","planned":false,"acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on December 3, 2025 and these shares underlying the option vested."}],"balance_after":70000,"derivative":{"exercise_price":0.7,"expiration_date":"2024-07-23","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001193125-25-310067","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000119312525310067/ownership.xml","form_type":"4"}},{"id":979098,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2025-12-05T23:54:26.000Z","date":"2025-09-26","kind":"grant","planned":false,"acquired":true,"shares":30000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On July 24, 2024 the Reporting Person was granted an option with vesting subject to the satisfaction of performance-based vesting criteria. The performance-based vesting criteria for these shares was deemed satisfied or waived on September 26, 2025 and these shares underlying the option vested."}],"balance_after":30000,"derivative":{"exercise_price":0.7,"expiration_date":"2034-07-23","underlying":"Common Stock","underlying_shares":30000},"source":{"system":"sec-edgar","filing":"0001193125-25-310067","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000119312525310067/ownership.xml","form_type":"4"}},{"id":1192270,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2025-03-25T20:00:06.000Z","date":"2025-03-21","kind":"grant","planned":false,"acquired":true,"shares":200000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 21, 2025."}],"balance_after":200000,"derivative":{"exercise_price":0.99,"expiration_date":"2035-03-20","underlying":"Common Stock","underlying_shares":200000},"source":{"system":"sec-edgar","filing":"0000950170-25-044345","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000095017025044345/ownership.xml","form_type":"4"}},{"id":1486865,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2024-06-07T20:00:07.000Z","date":"2024-06-05","kind":"grant","planned":false,"acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on December 5, 2024."}],"balance_after":60000,"derivative":{"exercise_price":1.65,"expiration_date":"2034-06-04","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0000950170-24-070562","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000095017024070562/ownership.xml","form_type":"4"}},{"id":1586867,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2024-03-08T21:00:15.000Z","date":"2024-03-06","kind":"grant","planned":false,"acquired":true,"shares":175000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on September 6, 2024."}],"balance_after":175000,"derivative":{"exercise_price":1.94,"expiration_date":"2034-03-05","underlying":"Common Stock","underlying_shares":175000},"source":{"system":"sec-edgar","filing":"0000950170-24-028613","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000095017024028613/ownership.xml","form_type":"4"}},{"id":1823531,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2023-07-25T16:27:10.000Z","date":"2023-07-21","kind":"grant","planned":false,"acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in twenty four equal monthly installments beginning on August 21, 2023."}],"balance_after":75000,"derivative":{"exercise_price":4.2,"expiration_date":"2033-07-20","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0001209191-23-043274","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919123043274/doc4.xml","form_type":"4"}},{"id":2003638,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2023-02-21T22:00:22.000Z","date":"2023-02-16","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option becomes exercisable in eight equal semi-annual installments beginning on August 16, 2023."}],"balance_after":100000,"derivative":{"exercise_price":3.21,"expiration_date":"2033-02-15","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-23-011249","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919123011249/doc4.xml","form_type":"4"}},{"id":2315392,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-29T20:13:47.000Z","date":"2022-03-25","kind":"grant","acquired":true,"shares":16667,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"2. This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 25, 2022."}],"balance_after":16667,"derivative":{"exercise_price":5.01,"expiration_date":"2032-03-24","underlying":"Common Stock","underlying_shares":16667},"source":{"system":"sec-edgar","filing":"0001209191-22-021456","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919122021456/doc4.xml","form_type":"4"}},{"id":2315391,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, GENERAL COUNSEL"}}],"security":"Stock Option (right to buy)","published_at":"2022-03-29T20:13:47.000Z","date":"2022-02-09","kind":"grant","acquired":true,"shares":60000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"1. This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 9, 2022."}],"balance_after":60000,"derivative":{"exercise_price":6.91,"expiration_date":"2032-02-08","underlying":"Common Stock","underlying_shares":60000},"source":{"system":"sec-edgar","filing":"0001209191-22-021456","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919122021456/doc4.xml","form_type":"4"}},{"id":2863516,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2021-02-12T22:43:51.000Z","date":"2021-02-10","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 10, 2021."}],"balance_after":50000,"derivative":{"exercise_price":15.55,"expiration_date":"2031-02-09","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000899243-21-006355","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000089924321006355/doc4.xml","form_type":"4"}},{"id":3063594,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-10T20:03:09.000Z","date":"2020-08-05","kind":"exercise","acquired":false,"shares":13374,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the \"Original Form 4\") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018."}],"balance_after":130000,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-27","underlying":"Common Stock","underlying_shares":13374},"source":{"system":"sec-edgar","filing":"0001209191-20-045921","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045921/doc4a.xml","form_type":"4/A","original_submission_date":"2020-08-07"}},{"id":3063593,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-10T20:03:09.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":13374,"price":20,"value":267480.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the \"Original Form 4\") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error."},{"field":"kind","element":"transactionCoding","label":"F2","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":17125,"source":{"system":"sec-edgar","filing":"0001209191-20-045921","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045921/doc4a.xml","form_type":"4/A","original_submission_date":"2020-08-07"}},{"id":3063592,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-10T20:03:09.000Z","date":"2020-08-05","kind":"exercise","acquired":true,"shares":13374,"price":7.5,"value":100305.0,"ownership":{"direct":true},"footnotes":[{"field":"security","element":"securityTitle","label":"F1","text":"This Form 4 amends and restates the original Form 4 filed on August 7, 2020 (the \"Original Form 4\") to include 100 Stock Options and shares of Common Stock that were omitted from the Original Form 4 due to clerical error."}],"balance_after":30499,"source":{"system":"sec-edgar","filing":"0001209191-20-045921","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045921/doc4a.xml","form_type":"4/A","original_submission_date":"2020-08-07"}},{"id":3064911,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-07T21:44:40.000Z","date":"2020-08-05","kind":"exercise","acquired":false,"shares":13274,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018."}],"balance_after":130100,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-27","underlying":"Common Stock","underlying_shares":13274},"source":{"system":"sec-edgar","filing":"0001209191-20-045702","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045702/doc4.xml","form_type":"4"}},{"id":3064910,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-07T21:44:40.000Z","date":"2020-08-05","kind":"sale","acquired":false,"shares":13274,"price":20,"value":265480.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":17125,"source":{"system":"sec-edgar","filing":"0001209191-20-045702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045702/doc4.xml","form_type":"4"}},{"id":3064909,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-07T21:44:40.000Z","date":"2020-08-05","kind":"exercise","acquired":true,"shares":13274,"price":7.5,"value":99555.0,"ownership":{"direct":true},"balance_after":30399,"source":{"system":"sec-edgar","filing":"0001209191-20-045702","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045702/doc4.xml","form_type":"4"}},{"id":3067589,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-05T20:51:09.000Z","date":"2020-08-04","kind":"exercise","acquired":false,"shares":201,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018."}],"balance_after":143374,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-27","underlying":"Common Stock","underlying_shares":201},"source":{"system":"sec-edgar","filing":"0001209191-20-045144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045144/doc4.xml","form_type":"4"}},{"id":3067588,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2020-08-05T20:51:09.000Z","date":"2020-08-03","kind":"exercise","acquired":false,"shares":6425,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018."}],"balance_after":143575,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-27","underlying":"Common Stock","underlying_shares":6425},"source":{"system":"sec-edgar","filing":"0001209191-20-045144","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045144/doc4.xml","form_type":"4"}},{"id":3067587,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-05T20:51:09.000Z","date":"2020-08-04","kind":"sale","acquired":false,"shares":201,"price":20.05,"value":4030.05,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.10, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":17125,"source":{"system":"sec-edgar","filing":"0001209191-20-045144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045144/doc4.xml","form_type":"4"}},{"id":3067586,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-05T20:51:09.000Z","date":"2020-08-04","kind":"exercise","acquired":true,"shares":201,"price":7.5,"value":1507.5,"ownership":{"direct":true},"balance_after":17326,"source":{"system":"sec-edgar","filing":"0001209191-20-045144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045144/doc4.xml","form_type":"4"}},{"id":3067585,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-05T20:51:09.000Z","date":"2020-08-03","kind":"sale","acquired":false,"shares":6425,"price":20,"value":128500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 24, 2020."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.01, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":17125,"source":{"system":"sec-edgar","filing":"0001209191-20-045144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045144/doc4.xml","form_type":"4"}},{"id":3067584,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-08-05T20:51:09.000Z","date":"2020-08-03","kind":"exercise","acquired":true,"shares":6425,"price":7.5,"value":48187.5,"ownership":{"direct":true},"balance_after":23550,"source":{"system":"sec-edgar","filing":"0001209191-20-045144","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120045144/doc4.xml","form_type":"4"}},{"id":3253168,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-02-24T21:56:55.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":15025,"price":7.9,"value":118697.5,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"87 of these shares were inadvertantly omitted from the Original Form 4, which reported a purchase of 14,938 shares of common stock on June 10, 2019 at a weighted average price of $7.93."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.85 to $7.92, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4."}],"balance_after":17125,"source":{"system":"sec-edgar","filing":"0001209191-20-012027","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120012027/doc4a.xml","form_type":"4/A","original_submission_date":"2019-06-10"}},{"id":3253167,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2020-02-24T21:56:55.000Z","date":"2019-06-07","kind":"purchase","acquired":true,"shares":100,"price":7.35,"value":735.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction was inadvertantly omitted from the reporting person's original Form 4 filed on June 10, 2019 (the \"Original Form 4\")."}],"balance_after":2100,"source":{"system":"sec-edgar","filing":"0001209191-20-012027","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120012027/doc4a.xml","form_type":"4/A","original_submission_date":"2019-06-10"}},{"id":3277280,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2020-02-12T21:53:50.000Z","date":"2020-02-05","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in eight equal semi-annual installments beginning August 5, 2020."}],"balance_after":20000,"derivative":{"exercise_price":16.26,"expiration_date":"2030-02-05","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0001209191-20-008815","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919120008815/doc4.xml","form_type":"4"}},{"id":3495819,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2019-06-10T22:16:44.000Z","date":"2019-06-10","kind":"purchase","acquired":true,"shares":14938,"price":7.93,"value":118458.34,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.80 to $8.45, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4."}],"balance_after":16938,"source":{"system":"sec-edgar","filing":"0001209191-19-035958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919119035958/doc4.xml","form_type":"4"}},{"id":3495818,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Common Stock","published_at":"2019-06-10T22:16:44.000Z","date":"2019-06-06","kind":"purchase","acquired":true,"shares":2000,"price":7.1,"value":14200.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $7.04 to $7.16, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc. (the \"Issuer\"), any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (1) to this Form 4."}],"balance_after":2000,"source":{"system":"sec-edgar","filing":"0001209191-19-035958","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919119035958/doc4.xml","form_type":"4"}},{"id":3604420,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-08T21:10:47.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Represents a stock option award granted on December 27, 2017 that partially vested upon the achievement of certain performance based conditions as determined by the Compensation Committee of Cue Biopharma, Inc. on March 6, 2019. As of March 6, 2019, 65,000 of these options were vested and exercisable. The remaining 35,000 will become vested and exercisable only upon the achievement of certain performance based conditions."}],"balance_after":100000,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-27","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-018084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919119018084/doc4.xml","form_type":"4"}},{"id":3604419,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Option (right to buy)","published_at":"2019-03-08T21:10:47.000Z","date":"2019-03-06","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This stock option grant becomes exercisable in eight equal semi-annual installments beginning September 6, 2019."}],"balance_after":50000,"derivative":{"exercise_price":6.42,"expiration_date":"2029-03-06","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-018084","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919119018084/doc4.xml","form_type":"4"}},{"id":4121039,"issuer":{"id":6301,"kind":"organization","name":"Cue Biopharma, Inc.","symbol":"CUE"},"owners":[{"id":52891,"kind":"person","name":"Sandercock Colin","position":1,"cik":"0001724870","reported_name":"Sandercock Colin","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, General Counsel and Sec"}}],"security":"Stock Options","published_at":"2017-12-27T21:48:09.000Z","date":"2017-12-27","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"These Stock Options become exercisable in eight equal semi-annual installments beginning June 5, 2018."}],"balance_after":150000,"derivative":{"exercise_price":7.5,"expiration_date":"2024-12-27","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001209191-17-067417","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1724870/000120919117067417/doc4.xml","form_type":"4"}}]}